[Press release – not published yet] Novavax reports 96% efficacy against original strain of COVID-19, 86% efficacy against B.1.1.7 variant, and 55% efficacy against B1.351 variant

Press release: Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials

Commentaries: Novavax Reports Its COVID-19 Vaccine is 96% Efficacious, Based on Phase 3 Trial Results – TIME AND Novavax Says Vaccine Is 96% Effective At Preventing Original Covid-19 Virus – Forbes

Commentary on Twitter

Breaking: Novavax announces efficacy results in its vaccine trials.

* 100% protection against severe disease
* 96% effective against symptoms from original virus (higher than Pfizer/BioNTech or Moderna)
* 86% against B-117.
* 55% against B-1.351https://t.co/MexA9SjoCt

— Melody Schreiber (@m_scribe) March 11, 2021